Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy.
Analyst Price Forecast Suggests 29.26% Upside
As of December 23, 2024, the average one-year price target for Collegium Pharmaceutical is $43.10/share. The forecasts range from a low of $37.37 to a high of $52.50. The average price target represents an increase of 29.26% from its latest reported closing price of $33.34 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Collegium Pharmaceutical is 633MM, an increase of 5.56%. The projected annual non-GAAP EPS is 6.49.
What is the Fund Sentiment?
There are 564 funds or institutions reporting positions in Collegium Pharmaceutical. This is an increase of 36 owner(s) or 6.82% in the last quarter. Average portfolio weight of all funds dedicated to COLL is 0.18%, an increase of 0.27%. Total shares owned by institutions increased in the last three months by 5.11% to 55,892K shares. 
The put/call ratio of COLL is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
CALF - Pacer US Small Cap Cash Cows 100 ETF holds 3,375K shares representing 10.46% ownership of the company. In its prior filing, the firm reported owning 2,730K shares , representing an increase of 19.10%. The firm increased its portfolio allocation in COLL by 21.86% over the last quarter.
Eventide Asset Management holds 2,635K shares representing 8.17% ownership of the company. In its prior filing, the firm reported owning 2,635K shares , representing an increase of 0.03%. The firm increased its portfolio allocation in COLL by 20.86% over the last quarter.
Pacer Advisors holds 2,590K shares representing 8.03% ownership of the company. In its prior filing, the firm reported owning 3,408K shares , representing a decrease of 31.62%. The firm decreased its portfolio allocation in COLL by 14.96% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 2,054K shares representing 6.37% ownership of the company. In its prior filing, the firm reported owning 2,115K shares , representing a decrease of 2.97%. The firm increased its portfolio allocation in COLL by 4.59% over the last quarter.
Principal Financial Group holds 1,746K shares representing 5.41% ownership of the company. In its prior filing, the firm reported owning 1,681K shares , representing an increase of 3.72%. The firm decreased its portfolio allocation in COLL by 46.59% over the last quarter.
Collegium Pharmaceutical Background Information
(This description is provided by the company.)
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
